Aimmax Therapeutics Inc.
Durham, NC
- UEI
- VCBNGNMH78J9
- CAGE
- 8CZ09
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4220 Apex Hwy # 140, Durham, NC 27713, USA
- Website
- aimmaxrx.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Debiopharm International SA | Lausanne, VD | — |
| Curza Inc. | Salt Lake City, UT | — |
| Bioamp Diagnostics Inc. | San Carlos, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Arietis Corporation | Boston, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Aimmax Therapeutics Inc. is a minority-owned, woman-owned small disadvantaged business registered to receive federal government awards since July 2019. The company specializes in developing novel antibiotic and antifungal therapies to address critical public health needs, particularly in combating drug-resistant pathogens. Aimmax focuses on creating innovative treatments for serious infections, including drug-resistant gonorrhea, multidrug-resistant gram-positive infections, and invasive candidiasis. Their work involves the discovery and development of new classes of antibiotics and antifungal peptides that aim to overcome existing resistance mechanisms and provide alternative treatment options for life-threatening infections.
The company has received multiple federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) to support their research and development efforts. These grants have funded projects such as the development of AMX-2005, a novel antibiotic with potential as a single-dose treatment for drug-resistant gonorrhea. Other funded projects include the creation of an injectable antibiotic to treat serious multidrug-resistant gram-positive infections, the development of an oral antibiotic effective against both gonorrhea and chlamydia, and the optimization of novel antifungal peptides to combat resistant Candida species. Through these grants, Aimmax Therapeutics Inc. conducts various stages of drug development, including in vitro microbiology studies, formulation development, safety assessments, pharmacokinetic studies, and efficacy evaluations in animal models. The company's work aligns with critical public health priorities identified by organizations such as the CDC and WHO, addressing the urgent need for new antimicrobial therapies in an era of increasing antibiotic resistance.
Quick answers
Is Aimmax Therapeutics Inc. registered in SAM.gov?
Yes. Aimmax Therapeutics Inc.'s SAM.gov registration is active through December 29, 2026.
What is Aimmax Therapeutics Inc.'s most recent federal award?
Aimmax Therapeutics Inc.'s most recent federal grant award is A single dose therapy to treat drug resistant gonorrhea (R44AI184024), from National Institute of Allergy and Infectious Diseases (NIH), on April 1, 2024.
On GovTribe
See Aimmax Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors